Clinical research of Yiqi-Huoxue decoction combined with conventional treatment on patients with diabetic kidney disease

Objective To study the clinical effect of Yiqi-Huoxue decoction on inflammatory factors and renal function with diabetic kidney disease (DN). Methods A total of 95 patients with DN were divided into the control group (n=47) and the treatment group (n=48) randomly. The control group were treated with conventional medicine, and the treatment group were treated with conventional medicine combined with Yiqi-Huoxue decoction. The two groups were treated for 12 weeks. The clinical efficacy of the two groups after treatment were compared. The serum IL-8, TNF-α, CRP and BUN, SCr, UAER of the two groups before and after treatment were compared. The adverse reactions of the two groups during treatment were compared. Results The total efficacy rate of the treatment group was 87.5% (42/48), significantly higher than 51.1% (24/47) of the control group (χ2=14.866, P<0.01). After treatment, the serum L-8 (7.23 ± 2.84 ng/L vs. 11.63 ± 7.20 ng/L, t=3.933), TNF-α (16.71 ± 1.05 ng/L vs. 18.35 ± 1.20 ng/L, t=7.093), CRP (5.63 ± 1.21 mg/L vs. 6.70 ± 1.38 mg/L, t=4.021) of the treatment groupwere significantly lower than those of the control group (P<0.05). After treatment, the BUN (6.03 ± 0.66 mmol/L vs. 8.12 ± 0.78 mmol/L, t=14.109), SCr (90.17 ± 14.30 mmol/L vs. 101.34 ± 18.81 mmol/L, t=3.263), UAER (0.64 ± 0.19 g/24 h vs. 0.96 ± 0.22 g/24h, t=7.592) of the treatment groupwere significantly lower than those of the control group (P<0.01). The adverse reactions rates of treatment group was 6.3% (3/48), control group was 8.5% (4/47), and there was no significantly differences between two groups (χ2=0.178, P=0.673). Conclusions The Yiqi-Huoxue decoction for patients with DN has a good efficacy and low adverse reactions, can reduce the inflammatory factors, improve the inflammatory state and renal function, and it was worthy clinical application. Key words: Diabetic nephropathies; Yiqi-Huoxue decoction; Interleukin-8; Tumor necrosis factor-alpha; C-reactive protein